AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05530941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online suicide prevention campaign
Description: The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
Study NCT06286761 — intervention group
Intervention type: OTHER
Intervention: endothelial cell collection
Description: Participants may opt to have testing performed including blood sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
Study NCT05548296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR-368
Description: ACR-368 is an experimental drug
Study NCT05548296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368
Study NCT05548296 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OncoSignature
Description: Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue
Study NCT04981912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDMP + rituximab as a means of debulking prior to initiating venetoclax.
Description: * Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy > 5 cm or ALC > 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up.
Study NCT05368935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days
Study NCT06373679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switching to E-Cigarette
Description: Participants will receive eleven weeks of e-cigarette products with instructions to switch completely at switch date
Study NCT06373679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switching using Medication
Description: Participants will receive eleven weeks of FDA approved medication, either varenicline or combination NRT, with instructions to quit smoking cigarettes at quit date
Study NCT05189080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.
Study NCT05189080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews
Description: Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.
Study NCT05189080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
Study NCT05590494 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasonic tenotomy
Description: Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
Study NCT06324331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decidual sparing
Description: Endometrial free uterine closure technique
Study NCT06324331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non decidual sparing
Description: Routine uterine closure technique including endometrium
Study NCT04823182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: The Cardiac MRI protocol consists of static T2 weighted in all three planes and T2 weighted imaging with fat saturation in the short axis plane.
Study NCT05824572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic visit audio recordings for self-management in older adults
Description: The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
Study NCT05824572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
Study NCT06259123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA I&T
Description: 2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
Study NCT06411665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine
Description: Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.
Study NCT06411665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.
Study NCT05880238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
Study NCT05880238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will continue their education according to the preschool education curriculum.
Study NCT05758571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
Study NCT05564988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preconditionning
Description: Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days.
Study NCT05950113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration
Study NCT05950113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT05950113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT05950113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Receive IV
Study NCT05950113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05950113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Receive IV
Study NCT05950113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive IV
Study NCT05950113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive CART-BCMA/CS1 cells IV
Study NCT05950113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT05950113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05950113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04903028 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.
Study NCT04903028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS 10 Hz DLPFC
Description: 10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
Study NCT06366282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Counseling for Childhood Traumatic Injury
Description: Caregiver intervention will be provided by the counseling team that includes components of trauma narrative, psychoeducation, coping strategies, and resilience-building using, for burn patients.
Study NCT06366282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care for Childhood Traumatic Injury
Description: Control group receives the current standard of care provided by the counseling team
Study NCT05210907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNUH-CD19-CAR-T
Description: SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
Study NCT05136287 — intervention group
Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Patients are included after GLP1 agonists prescription , at the first dispensation
Study NCT05221710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group.
Study NCT06118736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary Medial Hemi-epiphysiodesis of the proximal femur
Description: Temporary Medial Hemi-epiphysiodesis of the proximal femur
Study NCT05759819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard stenting
Description: The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
Study NCT04805177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematoma evacuation
Description: early minimally invasive image guided hematoma evacuation in patients suffering from ICH
Study NCT05305651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab dose and administration per standard of clinical care
Study NCT04906343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
Study NCT04691271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care.
Study NCT05996133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 30 mL of 0.25% bupivacaine
Study NCT05996133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 0.5 mL (5 mg) preservative-free dexamethasone
Study NCT05996133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 0.1 mL epinephrine 1:400,000.
Study NCT05996133 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: 3 mL normal saline
Study NCT04994743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT113176
Description: CORT113176 lipid capsule formulation for oral administration
Study NCT04994743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT113176
Description: Placebo matching CORT113176 lipid capsule formulation for oral administration
Study NCT06041087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Exercise
Description: A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
Study NCT06124404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
Study NCT04830982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Diazoxide
Description: 500 micromoles added to one liter of cardioplegia
Study NCT04830982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to one liter of cardioplegia
Study NCT06041087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise
Description: A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
Study NCT05051995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label placebo
Description: Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
Study NCT05051995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No-treatment
Description: During the no-treatment phase, participants receive no treatment for 2 weeks.
Study NCT06142708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual trigger (human chorionic gonadotropin plus GnRH-agonist)
Description: Human chorionic gonadotropin will be added to GnRH-agonist as a dual trigger in participants previously having had a suboptimal response to GnRH-agonist trigger only
Study NCT06142708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH-agonist only trigger
Description: GnRH-agonist only will be used for final maturation
Study NCT05387070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon PTH
Description: TransCon PTH is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for SC injection.
Study NCT05387070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
Study NCT06041087 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High-Intensity Exercise
Description: A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
Study NCT06041087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate (Maltodextrin powder mixed with water)
Description: 50g consumed immediately after exercise and 1h after exercise.
Study NCT06041087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skim Milk
Description: 500ml consumed immediately after exercise and 1h after exercise.
Study NCT06041087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greek yogurt
Description: 200g consumed immediately after exercise and 1h after exercise.
Study NCT06041087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 500ml consumed immediately after exercise and 1h after exercise.
Study NCT05447013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus-2-specific T cells
Description: Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors
Study NCT05447013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC)
Description: standard of care (SOC)
Study NCT06092931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: Oral tablets
Study NCT06092931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral syrup
Study NCT06092931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Oral tablets
Study NCT06092931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral tablets
Study NCT06092931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral tablets
Study NCT05656092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP0612
Description: Test drug
Study NCT05656092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2202
Description: Placebo drug
Study NCT05656092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2204
Description: Reference drug
Study NCT05656092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2201
Description: Placebo drug
Study NCT02484196 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires
Study NCT04081883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biosensor algorithm
Description: The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
Study NCT06049927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.25ml)
Description: 7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
Study NCT06049927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.5ml)
Description: 15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
Study NCT06049927 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine(BV)
Description: 7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
Study NCT06049927 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine(BY)
Description: 7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
Study NCT06637254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma
Study NCT06637254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo comparator of study